Effect of Low-Dose Nebivolol in Patients with Acute Myocardial Infarction: A Multi-Center Observational Study
- Authors
- 심두선; 현대영; 정명호; 김효수; 장기욱; 최동주; 한규록; 안태훈; 배장환; 최시완; 박종선; 허승호; 채재건; 오석규; 차광수; 황진용
- Issue Date
- Jan-2020
- Publisher
- 전남대학교 의과학연구소
- Keywords
- Beta-Adrenergic Receptors; Heart Failure; Hypertension; Myocardial Infarction
- Citation
- 전남의대학술지, v.56, no.1, pp.55 - 61
- Journal Title
- 전남의대학술지
- Volume
- 56
- Number
- 1
- Start Page
- 55
- End Page
- 61
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17705
- DOI
- 10.4068/cmj.2020.56.1.55
- ISSN
- 2233-7385
- Abstract
- The optimal dose of beta blockers after acute myocardial infarction (MI) remains uncertain. We evaluated the effectiveness of low-dose nebivolol, a beta1 blocker and a vasodilator, in patients with acute MI. A total of 625 patients with acute MI from 14 teaching hospitals in Korea were divided into 2 groups according to the dose of nebivolol (nebistol®, Elyson Pharmaceutical Co., Ltd., Seoul, Korea): low-dose group (1.25 mg daily, n=219) and usual- to high-dose group (≥2.5 mg daily, n=406). The primary endpoints were major adverse cardiac and cerebrovascular events (MACCE, composite of death from any cause, non-fatal MI, stroke, repeat revascularization, rehospitalization for unstable angina or heart failure) at 12 months. After adjustment using inverse probability of treatment weighting, the rates of MACCE were not different between the low-dose and the usual- to high-dose groups (2.8% and 3.1%, respectively; hazard ratio: 0.92, 95% confidence interval: 0.38 to 2.24, p=0.860). The low-dose nebivolol group showed higher rates of MI than the usual- to high-dose group (1.2% and 0%, p=0.008). The 2 groups had similar rates of death from any cause (1.1% and 0.3%, p=0.273), stroke (0.4% and 1.1%, p=0.384), repeat PCI (1.2% and 0.8%, p=0.428), rehospitalization for unstable angina (1.2% and 1.0%, p=0.743) and for heart failure (0.6% and 0.7%, p=0.832). In patients with acute MI, the rates of MACCE for low-dose and usual- to high-dose nebivolol were not significantly different at 12-month follow-up.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17705)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.